Detalhe da pesquisa
1.
A European Registry Evaluating Symptomatic Effectiveness of Pharmacologically Treated Patients with Lower Urinary Tract Symptoms due to Benign Prostatic Enlargement: Lessons Learned.
J Urol
; 205(4): 1145-1152, 2021 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-33259270
2.
Minimally invasive prostatic urethral lift (PUL) efficacious in TURP candidates: a multicenter German evaluation after 2 years.
World J Urol
; 37(7): 1353-1360, 2019 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-30283994
3.
Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study.
BJU Int
; 119(5): 767-775, 2017 05.
Artigo
Inglês
| MEDLINE | ID: mdl-27862831
4.
[Avanafil for the treatment of erectile dysfunction in practice. Non-interventional study AVANTI]. / Avanafil zur Therapie der erektilen Dysfunktion in der Praxis : Nicht interventionelle Studie AVANTI.
MMW Fortschr Med
; 159(Suppl 5): 16-21, 2017 06.
Artigo
Alemão
| MEDLINE | ID: mdl-28643292
5.
Nocturia and its impact on health-related quality of life and health care seeking behaviour in German community-dwelling men aged 50 years or older.
World J Urol
; 32(5): 1155-62, 2014 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-25103609
6.
Impact of desmopressin on nocturia due to nocturnal polyuria in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH).
World J Urol
; 32(5): 1163-70, 2014 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-25135845
7.
Fixed-dose combination PRO 160/120 of sabal and urtica extracts improves nocturia in men with LUTS suggestive of BPH: re-evaluation of four controlled clinical studies.
World J Urol
; 32(5): 1149-54, 2014 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-24938176
8.
Nocturia: state of the art and critical analysis of current assessment and treatment strategies.
World J Urol
; 32(5): 1109-17, 2014 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-25216925
9.
Age-stratified normal values for prostate volume, PSA, maximum urinary flow rate, IPSS, and other LUTS/BPH indicators in the German male community-dwelling population aged 50 years or older.
World J Urol
; 29(2): 171-8, 2011 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-21221974
10.
Association of polymorphisms in CYP19A1 and CYP3A4 genes with lower urinary tract symptoms, prostate volume, uroflow and PSA in a population-based sample.
World J Urol
; 29(2): 143-8, 2011 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-19921206
11.
From pathogenesis to prevention of castration resistant prostate cancer.
Prostate
; 70(1): 100-12, 2010 Jan 01.
Artigo
Inglês
| MEDLINE | ID: mdl-19760632
12.
Common genetic polymorphisms of AURKA and prostate cancer risk.
Cancer Causes Control
; 20(2): 147-52, 2009 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-18802780
13.
Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study.
Eur Urol
; 68(4): 643-52, 2015 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-25937539
14.
[Discussion of IQWiG preliminary report on treatment of benign prostatic hyperplasia. Are new procedures no better than standard surgery? (interview by Dr. Thomas Meissner)]. / Diskussion um IQWiG-Vorbericht zur BPS-Behandlung. Sind die neuen Verfahren nicht besser als die Standard-OP?
MMW Fortschr Med
; 149(24): 6-7, 2007 Jun 14.
Artigo
Alemão
| MEDLINE | ID: mdl-17668739
15.
The evolving role of oestrogens and their receptors in the development and progression of prostate cancer.
Eur Urol
; 55(3): 533-42, 2009 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-19013008
16.
The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries.
Eur Urol
; 51(1): 207-15; discussion 215-6, 2007 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-16846678
17.
Characteristics of patients presenting with LUTS/BPH in six European countries.
Eur Urol
; 50(3): 555-61; discussion 562, 2006 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-16782265
18.
Prostate size and PSA serum levels in male patients with spinal cord injury.
Urology
; 62(5): 845-8, 2003 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-14624906
19.
Expert opinion on 6-monthly luteinizing hormone-releasing hormone agonist treatment with the single-sphere depot system for prostate cancer.
BJU Int
; 100 Suppl 1: 1-5, 2007 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-17593201